HRP20010113A2 - Process for purifying human papillomavirus virus-like particles - Google Patents

Process for purifying human papillomavirus virus-like particles Download PDF

Info

Publication number
HRP20010113A2
HRP20010113A2 HR20010113A HRP20010113A HRP20010113A2 HR P20010113 A2 HRP20010113 A2 HR P20010113A2 HR 20010113 A HR20010113 A HR 20010113A HR P20010113 A HRP20010113 A HR P20010113A HR P20010113 A2 HRP20010113 A2 HR P20010113A2
Authority
HR
Croatia
Prior art keywords
vlps
hpv
protein
vlp
hpv type
Prior art date
Application number
HR20010113A
Other languages
English (en)
Croatian (hr)
Inventor
James C Cook
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HRP20010113A2 publication Critical patent/HRP20010113A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR20010113A 1998-08-14 1999-08-10 Process for purifying human papillomavirus virus-like particles HRP20010113A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9656898P 1998-08-14 1998-08-14
PCT/US1999/017930 WO2000009671A1 (en) 1998-08-14 1999-08-10 Process for purifying human papillomavirus virus-like particles

Publications (1)

Publication Number Publication Date
HRP20010113A2 true HRP20010113A2 (en) 2002-02-28

Family

ID=22257989

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010113A HRP20010113A2 (en) 1998-08-14 1999-08-10 Process for purifying human papillomavirus virus-like particles

Country Status (24)

Country Link
US (1) US6602697B1 (da)
EP (1) EP1105466B1 (da)
JP (1) JP4440471B2 (da)
KR (1) KR20010072470A (da)
CN (1) CN1354787A (da)
AT (1) ATE324436T1 (da)
AU (1) AU760633B2 (da)
BR (1) BR9913026A (da)
CA (1) CA2339034C (da)
CY (1) CY1105084T1 (da)
CZ (1) CZ2001570A3 (da)
DE (1) DE69931053T2 (da)
DK (1) DK1105466T3 (da)
EA (1) EA200100236A1 (da)
ES (1) ES2262333T3 (da)
HR (1) HRP20010113A2 (da)
HU (1) HUP0103091A3 (da)
IL (1) IL141130A0 (da)
NZ (1) NZ509610A (da)
PL (1) PL347472A1 (da)
PT (1) PT1105466E (da)
SI (1) SI1105466T1 (da)
SK (1) SK2232001A3 (da)
WO (1) WO2000009671A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) * 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
JP2000262280A (ja) * 1999-03-18 2000-09-26 Asahi Optical Co Ltd ウィルスまたはウィルス性抗原の精製方法およびワクチンの製造方法
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
EP2821135A1 (en) * 2004-02-05 2015-01-07 EMD Millipore Corporation Porous adsorptive or chromatographic media
EP1730175B1 (en) * 2004-03-24 2010-04-28 Merck Sharp & Dohme Corp. Optimized expression of hpv 52 l1 in yeast
ATE474596T1 (de) 2004-09-10 2010-08-15 Asahi Glass Co Ltd Impfstoff gegen humanes papillomavirus zur oralen verabreichung
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2008027861A1 (en) * 2006-08-30 2008-03-06 Ge Healthcare Bio-Sciences Corp. System and method for characterizing membranes and membrane filtration devices
SG10202012986SA (en) 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
WO2008101667A1 (en) * 2007-02-22 2008-08-28 Baxter International Inc. Method of purification of hydrophobic proteins
DK2134360T3 (da) * 2007-03-14 2016-02-22 Takeda Vaccines Inc Oprensning af viruslignende partikel
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
BRPI0810951B8 (pt) * 2007-05-29 2021-05-25 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
EP2011573B1 (en) * 2007-11-05 2010-07-21 Agilent Technologies, Inc. Freezing a microfluidic chip
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2011088225A1 (en) 2010-01-15 2011-07-21 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
JP5881744B2 (ja) 2011-02-02 2016-03-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド アルカリ溶液でのアパタイトの表面中和方法
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
SG11201401579UA (en) * 2011-12-01 2014-07-30 Univ Cape Town Hpv chimaeric particle
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
US10099157B2 (en) 2014-06-23 2018-10-16 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
CN105392569B (zh) 2014-06-23 2019-08-20 生物辐射实验室股份有限公司 磷灰石预处理
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
CN108524929B (zh) * 2017-03-06 2019-05-07 广州瑞贝斯药业有限公司 一种狂犬病疫苗的生产方法
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
JP6704074B2 (ja) * 2019-02-04 2020-06-03 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6078999A (ja) 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
SE9000650L (sv) * 1989-02-28 1990-08-29 Asahi Optical Co Ltd Separation av celler eller virus
JP3863559B2 (ja) * 1994-05-16 2006-12-27 メルク エンド カンパニー インコーポレーテッド 乳頭腫ウィルスワクチン
NZ293461A (en) * 1994-09-22 1998-04-27 Merck & Co Inc Dna encoding human papillomavirus type 6a, compounds derived therefrom
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
AU722196B2 (en) * 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV

Also Published As

Publication number Publication date
CY1105084T1 (el) 2009-11-04
EP1105466A4 (en) 2002-05-15
HUP0103091A2 (hu) 2001-12-28
NZ509610A (en) 2002-10-25
EA200100236A1 (ru) 2001-08-27
BR9913026A (pt) 2001-09-25
DE69931053T2 (de) 2006-11-23
SI1105466T1 (sl) 2006-08-31
EP1105466A1 (en) 2001-06-13
SK2232001A3 (en) 2001-08-06
DK1105466T3 (da) 2006-08-14
HUP0103091A3 (en) 2002-03-28
ATE324436T1 (de) 2006-05-15
CA2339034C (en) 2010-10-12
US6602697B1 (en) 2003-08-05
WO2000009671A1 (en) 2000-02-24
KR20010072470A (ko) 2001-07-31
AU760633B2 (en) 2003-05-22
PT1105466E (pt) 2006-07-31
JP4440471B2 (ja) 2010-03-24
CA2339034A1 (en) 2000-02-24
AU5469899A (en) 2000-03-06
PL347472A1 (en) 2002-04-08
DE69931053D1 (de) 2006-06-01
ES2262333T3 (es) 2006-11-16
CN1354787A (zh) 2002-06-19
IL141130A0 (en) 2002-02-10
EP1105466B1 (en) 2006-04-26
CZ2001570A3 (cs) 2001-09-12
JP2003520188A (ja) 2003-07-02

Similar Documents

Publication Publication Date Title
HRP20010113A2 (en) Process for purifying human papillomavirus virus-like particles
Cook et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae
JP5284290B2 (ja) ウイルス様粒子の精製
Li et al. Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses
Hong et al. The 100K-chaperone protein from adenovirus serotype 2 (Subgroup C) assists in trimerization and nuclear localization of hexons from subgroups C and B adenoviruses
Sviben et al. Recovery of infective virus particles in ion-exchange and hydrophobic interaction monolith chromatography is influenced by particle charge and total-to-infective particle ratio
JPS61158795A (ja) アデノウイルスプロモ−タ−の制御下で所定のポリペプチドをコ−ドしているヌクレオチド配列を含む組換えｄｎａ
Lin et al. Development of EV71 virus-like particle purification processes
GB2604692A (en) Method for preparing recombinant subunit vaccine against novel coronavirus
KR20230118619A (ko) 아데노바이러스의 정제 방법
CN107190013A (zh) 一种以人Ad5复制缺陷型腺病毒为载体的寨卡病毒病疫苗
Effio et al. High-throughput process development of an alternative platform for the production of virus-like particles in Escherichia coli
US20080044378A1 (en) Methods and Compositions for Protein Production Using Adenoviral Vectors
SUN et al. Sequences required for the nuclear targeting and accumulation of human papillomavirus type 6B L2 protein
JPS63500662A (ja) 乳頭腫ウイルスの特徴を示すポリペプチドを含む組成物
AU753391B2 (en) Protein delivery system using human papillomavirus virus-like particles
Singh et al. A newly identified interaction between IVa2 and pVIII proteins during porcine adenovirus type 3 infection
Swartz et al. Binding of Coxsackievirus A21 procapsids to immobilized glutathione depends on cell culture conditions during infection
US5077213A (en) Recombinant vaccinia virus
JP4268384B2 (ja) 日本脳炎ウイルス抗原及びその製造方法
MXPA01001647A (en) Process for purifying human papillomavirus virus-like particles
Chen et al. Innovative MgCl2-mediated two-step precipitation-dissolution strategy for efficient purification of Porcine Circovirus Type 2 capsid protein and self-assembly of virus-like particles
Edeling et al. Development of methods to purify SARS CoV-2 Virus-like particles at scale
WO2015128788A1 (en) Purification of papillomavirus l2 protein
CA2182272C (en) Modified papilloma virus l2 protein and vlps formed therefrom

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn